New jerseydublin

NEW BRUNSWICK, New Jersey and DUBLIN - - First-in-Class Alzheimer's Treatments Expand Existing J&J Neuroscience Pipeline - Johnson & Johnson Equity Investment Provides Financial Flexibility for Elan Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) today announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP Program), through a newly formed company.